ArticleBMC pediatrics2025
Analysis of the therapeutic effect of online haemodiafiltration on delayed methotrexate excretion combined with acute kidney injury in children: a real-world study.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTo evaluate the efficacy and feasibility of online haemodiafiltration (HDF) in the treatment of delayed methotrexate (MTX) excretion and acute kidney injury (AKI) in children with hematological malignancies after chemotherapy.
methodsChildren diagnosed with hypermethotrexatemia combined with acute kidney injury and receiving blood purification treatment during high-dose methotrexate(HD-MTX) chemotherapy for leukemia/lymphoma in a hospital from January 2019 to August 2023 were divided into CRRT group and HDF group. The rate of decrease in MTX blood concentration, drug-related adverse reactions, renal function recovery time and hospitalization related economic costs were compared between the HDF group and CRRT group.
resultsThere was no significant differences (P > 0.05) between the HDF group and the CRRT group in terms of drug concentration after 45 h of MTX treatment, time required for MTX concentration to return to normal, time required for renal function to return to normal, length of hospital stay and the primary clinical endpoints between HDF and CRRT groups. In terms of total hospitalization costs and blood purification related expenses, the HDF group was significantly lower than the CRRT group (P < 0.05).
conclusionIn children with hypermethotrexatemia and AKI who cannot effectively clear MTX through conservative internal medicine treatment. online HDF appears to be a safe and cost-effective alternative to CRRT for MTX clearance in paediatric patients with delayed excretion and AKI, with similar clinical outcomes and lower associated costs. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.